- Home
- OKYO vs INKT Comparison
OKYO vs INKT Comparison
Compare OKYO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- INKT
- Stock Information
- Founded
- OKYO 2007
- INKT 2017
- Country
- OKYO United Kingdom
- INKT United States
- Employees
- OKYO N/A
- INKT N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- INKT Medicinal Chemicals and Botanical Products
- Sector
- OKYO Health Care
- INKT Health Care
- Exchange
- OKYO Nasdaq
- INKT Nasdaq
- Market Cap
- OKYO 37.0M
- INKT 33.6M
- IPO Year
- OKYO 2022
- INKT 2021
- Fundamental
- Price
- OKYO $1.50
- INKT $7.61
- Analyst Decision
- OKYO Strong Buy
- INKT Strong Buy
- Analyst Count
- OKYO 1
- INKT 2
- Target Price
- OKYO $7.00
- INKT $37.50
- AVG Volume (30 Days)
- OKYO 58.3K
- INKT 4.9K
- Earning Date
- OKYO 05-06-2025
- INKT 05-13-2025
- Dividend Yield
- OKYO N/A
- INKT N/A
- EPS Growth
- OKYO N/A
- INKT N/A
- EPS
- OKYO N/A
- INKT N/A
- Revenue
- OKYO N/A
- INKT N/A
- Revenue This Year
- OKYO N/A
- INKT N/A
- Revenue Next Year
- OKYO N/A
- INKT N/A
- P/E Ratio
- OKYO N/A
- INKT N/A
- Revenue Growth
- OKYO N/A
- INKT N/A
- 52 Week Low
- OKYO $0.81
- INKT $4.56
- 52 Week High
- OKYO $1.74
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- OKYO 65.97
- INKT 44.24
- Support Level
- OKYO $1.03
- INKT $7.23
- Resistance Level
- OKYO $1.24
- INKT $7.68
- Average True Range (ATR)
- OKYO 0.11
- INKT 0.56
- MACD
- OKYO 0.03
- INKT -0.06
- Stochastic Oscillator
- OKYO 70.12
- INKT 21.66
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.